Logo image of ALINT.PA

INTEGRAGEN (ALINT.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALINT - FR0010908723 - Common Stock

0.1545 EUR
0 (-1.9%)
Last: 11/28/2025, 7:00:00 PM
Fundamental Rating

1

ALINT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. ALINT may be in some trouble as it scores bad on both profitability and health. ALINT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALINT had negative earnings in the past year.
ALINT had negative earnings in 4 of the past 5 years.
In the past 5 years ALINT always reported negative operating cash flow.
ALINT.PA Yearly Net Income VS EBIT VS OCF VS FCFALINT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2023 2024 0 -500K -1M -1.5M -2M

1.2 Ratios

Looking at the Return On Assets, with a value of -4.71%, ALINT is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
ALINT's Return On Equity of -14.77% is fine compared to the rest of the industry. ALINT outperforms 70.37% of its industry peers.
Industry RankSector Rank
ROA -4.71%
ROE -14.77%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALINT.PA Yearly ROA, ROE, ROICALINT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of ALINT (62.53%) is comparable to the rest of the industry.
ALINT's Gross Margin has declined in the last couple of years.
ALINT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-1.96%
ALINT.PA Yearly Profit, Operating, Gross MarginsALINT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2023 2024 0 20 -20 40 -40 60

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALINT has about the same amount of shares outstanding.
ALINT has more shares outstanding than it did 5 years ago.
ALINT has a better debt/assets ratio than last year.
ALINT.PA Yearly Shares OutstandingALINT.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2023 2024 2M 4M 6M
ALINT.PA Yearly Total Debt VS Total AssetsALINT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of 1.22, we must say that ALINT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.22, ALINT is in line with its industry, outperforming 58.02% of the companies in the same industry.
ALINT has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
ALINT has a Debt to Equity ratio (0.11) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 1.22
ROIC/WACCN/A
WACCN/A
ALINT.PA Yearly LT Debt VS Equity VS FCFALINT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2023 2024 1M 2M 3M

2.3 Liquidity

ALINT has a Current Ratio of 1.48. This is a normal value and indicates that ALINT is financially healthy and should not expect problems in meeting its short term obligations.
ALINT has a Current ratio of 1.48. This is in the lower half of the industry: ALINT underperforms 62.96% of its industry peers.
ALINT has a Quick Ratio of 1.42. This is a normal value and indicates that ALINT is financially healthy and should not expect problems in meeting its short term obligations.
ALINT has a Quick ratio (1.42) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.42
ALINT.PA Yearly Current Assets VS Current LiabilitesALINT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2023 2024 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ALINT have decreased strongly by -33.33% in the last year.
The Revenue for ALINT has decreased by -30.62% in the past year. This is quite bad
ALINT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.99% yearly.
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)-30.62%
Revenue growth 3Y-8.41%
Revenue growth 5Y0.99%
Sales Q2Q%-35.97%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALINT.PA Yearly Revenue VS EstimatesALINT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2023 2024 2M 4M 6M 8M 10M
ALINT.PA Yearly EPS VS EstimatesALINT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALINT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALINT.PA Price Earnings VS Forward Price EarningsALINT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALINT.PA Per share dataALINT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALINT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTEGRAGEN

EPA:ALINT (11/28/2025, 7:00:00 PM)

0.1545

0 (-1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-01 2025-10-01
Earnings (Next)04-27 2026-04-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.04M
Revenue(TTM)8.70M
Net Income(TTM)-260.00K
Analysts86.67
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.29
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.71%
ROE -14.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.53%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-1.96%
F-ScoreN/A
Asset Turnover1.58
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.42
Altman-Z 1.22
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-30.62%
Revenue growth 3Y-8.41%
Revenue growth 5Y0.99%
Sales Q2Q%-35.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-566.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

INTEGRAGEN / ALINT.PA FAQ

What is the fundamental rating for ALINT stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALINT.PA.


What is the valuation status of INTEGRAGEN (ALINT.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to INTEGRAGEN (ALINT.PA). This can be considered as Overvalued.


How profitable is INTEGRAGEN (ALINT.PA) stock?

INTEGRAGEN (ALINT.PA) has a profitability rating of 1 / 10.